SAM CHUN DANG PHARM CO (000250) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SAM CHUN DANG PHARM CO (000250) reported revenue of 231.8 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025231.8 billion KRW8.5 billion KRW12.0 billion KRW[source]
2024210.9 billion KRW2.6 billion KRW-5.1 billion KRW[source]
2023192.7 billion KRW9.6 billion KRW-4.2 billion KRW[source]
2022177.3 billion KRW12.2 billion KRW8.8 billion KRW[source]
2021167.3 billion KRW-15.3 billion KRW-10.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025413.3 billion KRW178.8 billion KRW234.5 billion KRW[source]
2024385.8 billion KRW156.7 billion KRW229.1 billion KRW[source]
2023285.5 billion KRW101.2 billion KRW184.3 billion KRW[source]
2022264.1 billion KRW117.2 billion KRW146.9 billion KRW[source]
2021222.3 billion KRW81.7 billion KRW140.6 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20259.8 billion KRW-42.4 billion KRW22.8 billion KRW[source]
202421.8 billion KRW-23.2 billion KRW65.8 billion KRW[source]
202323.4 billion KRW-8.4 billion KRW3.4 billion KRW[source]
202213.3 billion KRW-53.9 billion KRW13.3 billion KRW[source]
2021-7.7 billion KRW-30.1 billion KRW27.7 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice